Objective: To produce high-quality, real-world evidence for oncologists by collating scattered gynaecologic oncology (GO) medical records in China.
Design: Retrospective study.
Setting: The National Union of Real-world Gynaecological Oncology Research and Patient Management Platform (NUWA platform).
Sample: Patient-centred data pool.
Methods: The NUWA platform integrated inpatient/outpatient clinical, gene and follow-up data. Data of 11 456 patients with ovarian cancer (OC) were collected and processed using 91 345 electronic medical records. Structured and unstructured data were de-identified and re-collated into a patient-centred data pool using a predefined GO data model by technology-aided abstraction.
Main outcome measures: Recent treatment pattern shifts towards precision medicine for OC in China.
Results: Thirteen first-tier hospitals across China participated in the NUWA platform up to 7 December 2021. In total, 3504 (30.59%) patients were followed up by a stand-alone patient management centre. The percentage of patients undergoing breast cancer gene (BRCA) mutation tests increased by approximately six-fold between 2017 and 2018. A similar trend was observed in the administration rate of poly(ADP-ribose) polymerase inhibitors as first-line treatment and second-line treatment after September 2018, when olaparib was approved for clinical use in China.
Conclusion: The NUWA platform has great potential to facilitate clinical studies and support drug development, regulatory reviews and healthcare decision-making.
Keywords: breast cancer gene testing; gynaecologic oncology; ovarian cancer; real-world study; treatment patterns.
© 2022 John Wiley & Sons Ltd.